Editors Highlights-October 2026.

The treatment of inflammatory skin diseases has moved from broad immunosuppression toward mechanism-based therapy with targeted biologics and small molecules. Psoriasis exemplifies this shift: interleukin-23 (IL-23)/T helper 17 (Th17) blockade can achieve near-complete clearance, yet persistent tissue-resident memory T cells may sustain disease memory and drive relapse after treatment withdrawal. The papers highlighted in this issue link tissue memory, genotype, treatment durability, and pathway-directed therapy across different skin diseases. Together, they emphasize that precision dermatology must look beyond visible clearance toward biological remission and durable disease control.